4896
K Pharma,Inc.
ケイファーマ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Dec 2023
1,000,000
Dec 2024
-
Dec 2025
-
Operating profit(thousand JPY)
Dec 2023
366,057
Dec 2024
-836,346
Dec 2025
-916,056
Operating profit margin(%)
Dec 2023
36.61
Dec 2024
-
Dec 2025
-
Profit before tax(thousand JPY)
Dec 2023
301,076
Dec 2024
-844,104
Dec 2025
-990,498
Profit(thousand JPY)
Dec 2023
260,330
Dec 2024
-846,455
Dec 2025
-993,227
Total assets(thousand JPY)
Dec 2023
3,313,902
Dec 2024
2,353,073
Dec 2025
2,939,220
Cash and cash equivalents(thousand JPY)
Dec 2023
3,266,408
Dec 2024
2,268,198
Dec 2025
2,791,835
Cash flows from operating activities(thousand JPY)
Dec 2023
454,425
Dec 2024
-983,719
Dec 2025
-918,005
Cash flows from investing activities(thousand JPY)
Dec 2023
-11,099
Dec 2024
-14,490
Dec 2025
-54,683
Cash flows from financing activities(thousand JPY)
Dec 2023
1,486,235
Dec 2024
-
Dec 2025
1,496,325
Return on equity(%)
Dec 2023
11.7
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2023
93.7
Dec 2024
96
Dec 2025
43.1
Earnings per share(JPY per share)
Dec 2023
25.42
Dec 2024
-72.94
Dec 2025
-85.59
Net assets per share(JPY per share)
Dec 2023
267.55
Dec 2024
194.6
Dec 2025
109
Dividend per share(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.